Disclosure {#j_raon-2020-0026_s_100}
==========

No potential conflicts of interest were disclosed.

Introduction {#j_raon-2020-0026_s_001}
============

Management of locally advanced (stage III) non-small cell lung carcinoma (NSCLC) includes a broad spectrum of diagnostic procedures and therapeutic modalities. Diagnosis is primarily based on computer tomography (CT) scan of chest plus upper abdomen and brain, bronchoscopy and CT-guided biopsies. For more precise exclusion of distant metastases, the evaluation with PET-CT is useful. Detailed locoregional staging is done by means of PET-CT[@j_raon-2020-0026_ref_001], endobronchial or endoscopic ultrasound (EBUS/EUS), mediastinoscopy, thoracoscopy, mediastinotomy or other biopsies of suspected nodal lesions in order to distinguish early stages (stages I and II) from stage IIIA/IIIB.[@j_raon-2020-0026_ref_002]

Treatment of NSCLC stage III requires multidisciplinary co-operation in order to deliver appropriate local and systemic therapies for the various subgroups. Occurrence of distant metastases with and without local progression is frequent, thereby leading to 5-year survival rates often less than 20%.[@j_raon-2020-0026_ref_003] According to the 7^th^ edition of the TNM classification[@j_raon-2020-0026_ref_003] stage III was subdivided into stage IIIA and IIIB. The 5-year survival rates were 36% and 19%, respectively.[@j_raon-2020-0026_ref_004] According to the 8^th^ edition, stage III is divided into IIIA, IIIB and IIIC. The 5-year survival rates are 36%, 26% and 13%, respectively.[@j_raon-2020-0026_ref_004] In operable stage IIIA, induction or adjuvant chemotherapy improve overall survival[@j_raon-2020-0026_ref_005], [@j_raon-2020-0026_ref_006] and are established as standard treatments. Important prognostic factors associated with prolonged survival are pathological down-staging of mediastinal lymph nodes and/or primary tumors, and complete tumour resection.[@j_raon-2020-0026_ref_007], [@j_raon-2020-0026_ref_008], [@j_raon-2020-0026_ref_009], [@j_raon-2020-0026_ref_010] Some trials assessing induction therapy followed by surgery have also included patients with stage IIIB disease and suggested that patients with operable stage IIIB NSCLC have outcomes similar to those with stage IIIAN2 disease.[@j_raon-2020-0026_ref_011] For patients with inoperable stage IIIA or stage IIIB and good performance status (PS), definitive chemoradiotherapy is the treatment of choice.[@j_raon-2020-0026_ref_002] Concurrent chemoradiotherapy is associated with longer survival at increased toxicity compared to the sequential approach.[@j_raon-2020-0026_ref_012] Radiotherapy dose escalation has no clear benefit.[@j_raon-2020-0026_ref_013] Sequential chemoradiotherapy or radiotherapy alone remain options for selected patients.[@j_raon-2020-0026_ref_002] Consolidation therapy with durvalumab after concurrent chemoradiotherapy has recently been shown to improve survival of patients[@j_raon-2020-0026_ref_014] and has been established as standard treatment.

There is evidence that management of NSCLC stage III varies between countries, geographical regions, cancer centres and even treating physicians. Reasons for these variations include differences in regional standards, access to diagnostic procedures as well as therapeutic modalities, and resources. The aim of the present study was to determine diagnostic and therapeutic procedures as well as clinical outcome including survival of patients with NSCLC stage III in the real-world setting in Central European countries and to define areas for future improvements in routine management of these patients.

Patients and methods {#j_raon-2020-0026_s_002}
====================

Patients {#j_raon-2020-0026_s_002_s_001}
--------

The present study was prospective, observational, non-interventional, multicentric, multinational and registry based. The study had been approved by ethics committees of participating centres and was performed in accordance with the Declaration of Helsinki. Study entry criteria were patients of any age, histological and/or cytological diagnosis of NSCLC stage III according to 7^th^ edition of the TNM classification[@j_raon-2020-0026_ref_003] and signed written informed consent. The study allowed enrolling patients who have been treated between March 2014 and March 2017. Follow-up of patients continued until February 2018.

Data collection {#j_raon-2020-0026_s_002_s_002}
---------------

Registration of all data was fully anonymous and performed in an electronic case report form (CRF \[eCRF\]) by qualified personnel. Patient identification was in the responsibility of each investigator. The following data were collected: age, gender, race, smoking status, PS, weight loss, date of NSCLC diagnosis, histology and mutational status of tumors, staging procedures, method of mediastinal lymph-node examination, TNM and tumor stage. Data collected on therapeutic procedures were primary therapy, surgical procedures (date, extent, completeness of resection, information on repeated resections), thoracic radiotherapy (date, dose, fractions, technique, energy), prophylactic cranial irradiation, and chemotherapy (dates of start and end, number of cycles, cytotoxic drugs). Combined modality therapy was assessed according to investigator statement and/or dates of overlapping therapies. Type of best treatment response, date of recurrence or progression, and dates of death were collected.

Statistical analyses {#j_raon-2020-0026_s_002_s_003}
--------------------

Descriptive statistics and frequency tables were used to characterize the sample data set. Statistical significances of differences for categorical and continuous parameters were assessed by means of Fisher's exact test and Mann-Whitney test, respectively. Overall survival (OS) was defined as the time from treatment initiation until death of any cause. Progression-free survival (PFS) was defined as the time from treatment initiation until first documented progression and/or death of any cause. Patients without an event were censored at the time of last follow-up visit. Patients lost to follow-up were counted as interval-censored observations. The assumption was made that patients were lost to follow-up due to their treatment failure and that, therefore, no information is available about them. Interval set (interval between visits) was 6 months.[@j_raon-2020-0026_ref_015] PFS and OS were estimated by Kaplan-Meier analysis and 95% confidence intervals (95% CI) were provided for all point estimates. Statistical significance of differences in survival between the subgroups was assessed by means of the log-rank test. The multivariable Cox proportional hazard model was used to evaluate the effects of potential prognostic factors on survival measures. Hazard ratios (HR) were complemented with 95% confidence intervals and supported with significance levels. Overall response rate (ORR) was defined as the sum of complete response rate (CR) and partial response rate (PR) and disease control rate as ORR plus stable disease rate (SD). All statistical tests were performed at the significance level of P = 0.05.

Results {#j_raon-2020-0026_s_003}
=======

Patients {#j_raon-2020-0026_s_003_s_001}
--------

A total of 617 patients were enrolled but 34 patients were excluded due to various violations of the study protocol. Thus the study population comprises 583 patients from 16 centres of seven Central European countries: eight centres from Czech Republic (269 patients), two centres from Serbia (109 patients), two centres from Hungary (48 patients) and one centre each from Slovenia (53 patients), Latvia (43 patients), Lithuania (38 patients) and Austria (23 patients). The date for final analysis was February 19, 2018. Minimum follow-up since initial diagnosis was 11 months. Patient characteristics are shown in [Table 1](#j_raon-2020-0026_tab_001){ref-type="table"}: 53.3% aged ≥

###### 

Patient characteristics

                                                   IIIA (N = 321)   IIIB (N = 262)   IIIA + IIIB (N = 583)   
  ------------------------------------------------ ---------------- ---------------- ----------------------- ---------
  **Age**                                                                                                    
      \< 65 years                                  155 (48.3)       117 (44.7)       272 (46.7)              
      ≥ 65 years                                   166 (51.7)       145 (55.3)       311 (53.3)              
      Mean ± SD (years)                            64.8 ± 10.5      65.1 ± 10.1      64.9 ± 10.3             0.429
      Median (years)                               65.4             66.0             65.6                    
  **Gender**                                                                                                 
      Female                                       92 (28.7)        96 (37.0)        188 (32.2)              
      Male                                         229 (71.3)       166 (63.6)       395 (67.8)              0.050
  **Smoking status**                                                                                         
      Current smoker                               161 (50.2)       147 (56.3)       308 (52.8)              
      Former smoker                                127 (39.6)       92 (35.2)        219 (37.6)              
      Never smoker                                 26 (8.1)         16 (6.1)         42 (7.2)                
      Unknown                                      7 (2.2)          7 (2.7)          14 (2.4)                0.446
  **Weight loss ≥10% within prior three months**                                                             
      No                                           243 (75.7)       163 (62.5)       406 (69.6)              
      Yes                                          50 (15.6)        70 (26.8)        120 (20.6)              
      Unknown                                      28 (8.7)         29 (11.0)        57 (9.8)                \<0.001
  **WHO performance status**                                                                                 
      0                                            86 (26.8)        60 (23.0)        146 (25.0)              
      1                                            194 (60.4)       144 (54.9)       338 (58.0)              
      2                                            31 (9.7)         41 (15.7)        72 (12.3)               
      3                                            10 (3.1)         17 (6.5)         27 (4.6)                0.025
  **Histology**                                                                                              
      Squamous cell carcinoma                      176 (54.8)       133 (51.0)       309 (53.0)              
      Adenocarcinoma                               115 (35.8)       105 (40.0)       220 (37.7)              
      NSCLC NOS                                    18 (5.6)         18 (6.9)         36 (6.2)                
      Other                                        12 (3.7)         6 (2.3)          18 (3.1)                0.477

\* = Chi-square test for IIIA *vs*. IIIB; NOS = not otherwise specified; NSCLC = non-small-cell lung cancer; SD = standard deviation

65 years, 32.2% females, 7.2% never-smokers, 20.6% weight loss (≥ 10% within prior three months), 83% PS WHO 0--1. Stages IIIA and IIIB were diagnosed in 321 (55.1%) and 262 (44.9%) patients, respectively. Females, patients with weight loss and patients with poor PS were slightly more frequent among patients with stage IIIB. Squamous cell carcinomas were diagnosed in 309 (53.0%) patients, adenocarcinomas in 220 (37.7%) patients, NSCLC not otherwise specified in 36 (6.2%) patients, and other types (e.g. adeno-squamous, large cell) in 18 (3.1%) patients. Results of molecular analyses were documented for 150 (25.7%) patients (data not shown). EGFR mutations were detected in 14/142 (9.9%) patients, KRAS mutations in 11/31 (35.5%) patients and ALK aberrations in 2/88 (2.3%) patients (data not shown).

Staging procedures {#j_raon-2020-0026_s_003_s_002}
------------------

Diagnostic and staging procedures are summarized in [Table 2](#j_raon-2020-0026_tab_002){ref-type="table"}. Widely used procedures were chest x-ray (96%), chest CT scan (97%), bronchos-copy (89%) and upper abdominal CT scan (67%). PET-CT or PET were performed in 28% of patients. Brain imaging by means of CT or MRI was done in 20% of patients. EBUS or EUS were performed in 14% of patients, CT-guided biopsy in 9%, video-assisted thoracoscopic surgery (VATS) in 3%, and mediastinoscopy in 2%. Other procedures included diagnostic thoracotomy in 5%, radical thoracic surgery with gain of histology in 1%, ultrasonog-raphy (other than abdominal) (1%) and extracranial MRI examinations. The frequencies of the procedures showed great variations between centres with particularly great variations for PET or PET-CT (0--78%), brain imaging (0--91%) and EBUS/EUS (0--71%) ([Table 2](#j_raon-2020-0026_tab_002){ref-type="table"}).

###### 

Diagnostic procedures

                            Patients(N = 583)   
  ------------------------- ------------------- -----------
  Chest CT scan             567 (97)            67 -- 100
  Chest X-ray               559 (96)            79 -- 100
  Bronchoscopy              521 (89)            65 -- 100
  Upper abdominal CT scan   389 (67)            0 -- 100
  Upper abdominal US        160 (27)            2 -- 87
  PET-CT or PET scan        163 (28)            0 -- 78
  Brain CT or MRI           117 (20)            0 -- 91
  Bone scan                 88 (15)             0 -- 79
  EBUS or EUS               80 (14)             0 -- 71
  CT-guided biopsy          54 (9)              0 -- 31
  VATS                      19 (3)              0 -- 35
  Mediastinoscopy           13 (2)              0 -- 13
  Others                    47 (8)              0 -- 30

EBUS = endobronchial ultrasound; EUS = endoscopic ultrasound; VATS = video-assisted thoracoscopic surgery

Stage IIIA and st age IIIB were diagnosed in 55.1% and 44.9% of patients, respectively ([Table 1](#j_raon-2020-0026_tab_001){ref-type="table"}). Subgroups based on T and N descriptors are shown in [Table 3](#j_raon-2020-0026_tab_003){ref-type="table"}. Stages T1--T3 were found in 340 patients (58.3%) mostly having N2 or N3 nodal stage in 301 (51.6%) patients. T4N0, T4N1 and T4N2 tumours were found in 33 (5.7%), 26 (4.5%) and 129 (22.2%) patients, respectively. T3N3 and T4N3 tumours were diagnosed in 29 (5%) and 55 (9.4%) patients, respectively. T3--4N3 tumours (stage IIIC according to 8^th^ TNM classification) were diagnosed in 84 (14.4%) patients. N2 or N3 lymph nodes were found in 485 (83.2%) patients. Histopathological involvement of mediastinal lymph nodes was confirmed in 172 (29.5%) patients by surgery (96 patients), transbronchial biopsy (58 patients), mediastinoscopy (11 patients) or other types of biopsy (10 patients) (data not shown).

###### 

TNM subgroups (*Union for International Cancer Control* \[UICC\] 7)

                  Total patient population             Patients undergoing surgery   
  --------------- -------------------------- --------- ----------------------------- ----------
  **IIIA+IIIB**   **583 (100)**              **135**   **32.2**                      **NA**
  **IIIA**        **321 (55.1)**             **119**   **20.4**                      **37.1**
      T4N0        33 (5.7)                   10        1.7                           30.3
      T3N1        39 (6.7)                   16        2.7                           41.0
      T4N1        26 (4.5)                   7         1.2                           26.9
      T1N2        25 (4.3)                   14        2.4                           56.0
      T2N2        98 (16.8)                  45        7.7                           45.9
      T3N2        100 (17.2)                 27        4.6                           27.0
  **IIIB**        **262 (44.9)**             **16**    **2.8**                       **6.1**
      T4N2        129 (22.2)                 15        2.6                           11.6
      T1N3        17 (2.9)                             0                             0
      T2N3        32 (5.5)                             0.2                           3.1
      T3N3        29 (5.0)                                                           
      T4N3        55 (9.4)                                                           
  **T stage**                                                                        
      T1          42 (7.2)                   14        2.4                           33.3
      T2          130 (22.3)                 46        7.9                           35.4
      T3          168 (28.8)                 43        7.4                           25.6
      T4          243 (41.7)                 32        5.5                           13.1
  **N stage**                                                                        
      N0          33 (5.7)                   10        1.7                           30.3
      N1          65 (11.1)                  23        3.9                           35.4
      N2          352 (60.4)                 101       17.3                          28.7
      N3          133 (22.8)                 1         0.2                           0.8

NA = not applicable

Treatment {#j_raon-2020-0026_s_003_s_003}
---------

Therapeutic modalities are shown in overview for the total study population in [Figure 1](#j_raon-2020-0026_fig_001){ref-type="fig"}, for patients with stage IIIA and those with IIIB in detail in [Table 4](#j_raon-2020-0026_tab_004){ref-type="table"}. Time from diagnosis to treatment initiation ranged from 0 to 369 (median 23) days. Combined therapies of any type were delivered to 326 (55.9%) patients. With regard to a single treatment modality only, surgery was delivered to 1.5% thoracic radiotherapy to 11.8%, chemotherapy to 25.7% and best supportive care (BSC) to 5.0% of patients of the total study population. Prophylactic cranial irradiation was not delivered to any patient.

![Treatment modalities and combinations.](raon-54-209-g001){#j_raon-2020-0026_fig_001}

###### 

Therapeutic modalities and combinations

  Therapeutic modalities                          IIIA (N=321)         IIIB (N 262) N=(%)   IIIA+IIIB (N=583)
  ----------------------------------------------- -------------------- -------------------- -------------------------
  **Any combination**                             **207 (64.5)**       **119 (45.4)**       **326 (55.9)**
  **Surgery**                                     **119 (37.1)**       **16 (6.1)**         **135 (23.2)**
      Surgery alone                               9 (2.8)              0                    9 (1.5)
      Surgery plus radiotherapy                   7 (2.2)              1 (0.4)              8 (1.4)
      Surgery plus chemotherapy                   70 (21.8)            7 (2.7)              77 (13.2)
        Preoperative chemotherapy                 22 (6.9)             4 (1.5)              26 (4.4)
        Perioperative chemotherapy                3 (0.9)              0                    3 (0.5)
        Adjuvant chemotherapy                     45 (14.0)            3 (1.1)              48 (8.2)
      Surgery plus RT plus CT (trimodality)       33 (10.3)            8 (3.1)              41 (7.0)
        Sequential preoperative RT plus CT        2 (0.6)              0                    2 (0.3)
        Concurrent preoperative RT plus CT        3 (0.9)              1 (0.4)              4 (0.7)
        Sequential postoperative RT plus CT       23 (7.2)             3 (1.1)              26 (4.5)
        Concurrent postoperative RT plus CT       5 (1.6)              4 (1.5)              9 (1.5)
  **Thoracic RT** (including other modalities)    **174 (54.2)**       **144 (55.0)**       **318 (54.6)**
        Radiotherapy alone                        37 (11.5)            32 (12.2)            69 (11.8)
  **Chemoradiotherapy**                           **97 (30.2)**        **103 (39.3)**       **200 (34.3)**
        Sequential                                74 (23.1)            72 (27.5)            146 (25.0)
        Concurrent                                23 (7.2)             31 (11.8)            54 (9.3)
  **Chemotherapy** (including other modalities)   **256 (79.7)**       **212 (80.9)**       **468 (80.3)**
        Chemotherapy alone                        58 (18.1)            92 (35.1)            150 (25.7)
  **Best supportive care alone**                  **9 (2.8)**          **20 (7.6)**         **29 (5.0)**
  **Type of surgery**                             **IIIA (N = 119)**   **IIIB (N = 16)**    **IIIA+IIIB (N = 135)**
        Lobectomy                                 74 (62.3)            3 (18.7)             77 (57.0)
        Bi-lobectomy                              6 (5.0)              0                    6 (4.5)
        Pneumonectomy                             28 (23.5)            4 (25.0)             32 (23.7)
        Atypical radical resection                5 (4.2)              1 (6.2)              6 (4.5)
        Non-radical surgery\*                     6 (5.0)              8 (50.0)             14 (10.4)

\* = Non-radical surgery (n = 14) as biopsy (n = 4, all IIIB), exploration (n = 7, IIIA = 5, IIIB = 2) or palliative resection (n = 3, IIIA = 1, IIIB = 2); CT = chemotherapy; RT = radiotherapy

Surgery was performed in 135 (23.2%) patients (119 IIIA, 16 IIIB) and resulted in radical tumour resection in 121 patients and explorative surgery or non-radical resections in 14 patients ([Table 4](#j_raon-2020-0026_tab_004){ref-type="table"} and [Figure 1](#j_raon-2020-0026_fig_001){ref-type="fig"}). The types of surgery included lobectomy (77 patients), bi-lobectomies (6 patients), pneumonectomy (32 patients) and atypical radical resections (6 patients) ([Table 4](#j_raon-2020-0026_tab_004){ref-type="table"}). Surgery was delivered as single modality (nine patients), in combination with chemotherapy (77 patients) or radiotherapy (eight patients) or as trimodality therapy (41 patients). Adjuvant chemotherapy was about twice as frequent as pre-operative chemotherapy among patients undergoing surgery.

Thoracic radiotherapy was delivered to 318 (54.6%) patients with similar proportions among stage IIIA and stage IIIB ([Table 4](#j_raon-2020-0026_tab_004){ref-type="table"}). Thoracic radiotherapy was delivered as single modality (69 patients), as definitive chemoradiotherapy (200 patients) and as trimodality therapy (41 patients). Among patients undergoing definitive chemoradiotherapy, the sequential administration was much more frequent than the concurrent one (146 *versus* 54 patients). Among patients undergoing trimodality therapy, concurrent chemoradiotherapy was delivered in 13 patients ([Table 4](#j_raon-2020-0026_tab_004){ref-type="table"}).

Chemotherapy as the most frequent treatment modality was delivered to 468 (80.3%) patients with similar percentages among IIIA and IIIB ([Table 4](#j_raon-2020-0026_tab_004){ref-type="table"}). Chemotherapy was the only treatment modality in 150 patients. Carboplatin was used in 43.6% and cisplatin in 37.4% of patients (data not shown). Platins were combined with vinorelbine (33%), gemcitabine (22%), etoposide (11%) or paclitaxel (11%). Pemetrexed was used in 7.7% of patients in stage IIIB and 2.5% in stage IIIA. Other drugs including docetaxel, vinblastine and bevacizumab were each used in less than 2% of patients. No relevant differences in chemotherapy protocols between stage IIIA and IIIB patients were seen (data not shown).

Treatment outcome {#j_raon-2020-0026_s_003_s_004}
-----------------

At a median follow-up time of 30 months, 154 (26.4%) patients were alive, 295 (50.6%) patients were dead and 134 (23%) patients were lost to follow-up. Among 334 patients evaluable for overall best response, complete remission, partial remission, stable disease and progressive disease were seen in 27.5%, 35.9%, 24.9% and 11.7% patients, respectively. Information on progression during follow-up was available for 338 patients, while no information was available for the other patients due to death (171 patients) or loss to follow-up (74 patients). Eighty-two (24.3%) patients were without progression and 256 (75.7%) patients had progression, either local (40.2%), distant (26.6%) or both (8.9%). Progression after end of treatment was more frequent among patients with stage IIIB than those with stage IIIA (91.2% *versus* 81.6%).

Survival analyses {#j_raon-2020-0026_s_003_s_005}
-----------------

OS and PFS are shown in [Table 5](#j_raon-2020-0026_tab_005){ref-type="table"}, [Table 6](#j_raon-2020-0026_tab_006){ref-type="table"} and [Figure 2](#j_raon-2020-0026_fig_002){ref-type="fig"}. Median OS was 16.8 months and the 3-year OS rate was 21%. Median PFS was 11.2 months and the 3-year PFS rate was 11.5%. OS and PFS were longer among patients with IIIA than among those with IIIB and the corresponding hazard ratios were 0.70 (95% CI 0.58--0.85; p \< 0.001) and 0.71 (95% CI 0.59--0.85; p \< 0.001), respectively ([Table 5](#j_raon-2020-0026_tab_005){ref-type="table"}; [Table 6](#j_raon-2020-0026_tab_006){ref-type="table"}). Among patients with stage IIIA, median OS was 20 months and the 3-year OS rate was 27%. The corresponding values for patients with stage IIIB were 14.4 months and 13.5%, respectively. Among patients with T3--4/N3 tumours who are classified as stage IIIC based on the 8^th^ edition of the TNM classification, survival outcome (median OS 11.6 months; 3-year OS rate 9.4%) was worse than the outcome of patients with stage IIIB based on the 7^th^ TNM classification.

![Overall survival and progression-free survival.](raon-54-209-g002){#j_raon-2020-0026_fig_002}

###### 

Overall survival according to stage and treatment modalities

                                                    N     Median              1-year              2-year              3-year
  ------------------------------------------------- ----- ------------------- ------------------- ------------------- -------------------
  **IIIA**                                                                                                            
        Total**\***                                 321   20.0 (17.1; 21.4)   70.7 (65.9; 75.9)   39.4 (34.3; 45.2)   27.0 (21.8; 33.3)
        Good                                        223   21.4 (20.1; 25.8)   76.3 (70.9; 82.1)   45.6 (39.4; 52.8)   33.8 (27.7; 41.3)
        Poor                                        75    13.3 (11.4; 17.7)   57.3 (47.2; 69.7    23.2 (15.2; 35.2)   9.1 (3.2; 26.0)
  **IIIB**                                                                                                            
        Total**\***                                 262   14.4 (13.0; 15.9)   58.2 (52.3; 64.5)   27.5 (22.5; 33.7)   13.5 (9.0; 20.2)
        Good                                        146   17.8 (14.8; 19.6)   67.0 (59.8; 75.1)   33.1 (26.1; 42.0)   19.6 (13.2; 29.1)
        Poor                                        97    10.4 (8.8; 19.6)    44.1 (35.2; 55.2)   17.3 (11.1; 27.0)   8.1 (3.0; 21.6)
        T3N3 and T4N3\*\*                           84    11.6 (9.8; 15.9)    48.5 (38.8; 60.5)   22.6 (15.2; 33.8)   9.4 (3.9; 22.7)
  **IIIA+IIIB**                                                                                                       
        Total**\***                                 583   16.8 (15.3; 18.5)   65.1 (61.3; 69.1)   34.1 (30.4; 38.2)   21.0 (17.3; 25.4)
        Good                                        369   20.1 (18.0; 21.5)   72.6 (68.2; 77.3)   40.7 (35.9; 46.2)   28.3 (23.6; 34.0)
        Poor                                        172   11.8 (10.2; 14.2)   50.0 (42.9; 57.9)   19.9 (14.6; 27.0)   8.0 (3.6; 17.8)
  **Surgery**                                                                                                         
        All surgeries                               135   29.0 (27.1; NA)     82.2 (76.0; 88.9)   60.6 (52.8; 69.6)   43.9 (35.2; 54.8)
        Alone                                       9     13.9 (3.2; NA)      55.6 (31.0; 99.7)   22.2 (6.6; 75.4)    22.2 (6.6; 75.4)
        Surgery plus CT or RT                       85    27.8 (23.6; NA)     80.0 (71.9; 89.0)   57.2 (47.5; 68.9)   37.0 (26.7; 51.3)
        Surgery plus adjuvant CT                    77    28.3 (24.7; NA)     81.8 (73.6; 90.9)   60.6 (50.6; 72.7)   38.9 (28.0; 54.0)
        Trimodality therapy                         41    Not reached         92.7 (85.0; 100)    76.9 (64.7; 91.5)   64.8 (49.9; 84.2)
  **Non-surgical therapy**                                                                                            
        All non-surgical                            448   14.6 (13.7; 15.9)   59.9 (55.5; 64.7)   26.0 (22.1; 30.5)   13.8 (10.2; 18.8)
        CT alone                                    150   12.7 (11.3; 13.9)   56.5 (49.1; 65.0)   19.1 (13.7; 26.8)   6.2 (2.7; 14.4)
        RT alone                                    69    12.7 (9.6; 18.4)    52.2 (41.6; 65.4)   18.8 (11.6; 30.7)   11.8 (5.9; 23.5)
        CRT all                                     200   19.6 (17.5; 21.6)   72.9 (67.0; 79.3)   36.9 (30.7; 44.5)   22.6 (16.1; 31.6)
        CRT sequential                              146   20.5 (17.2; 22.8)   75.2 (68.5; 82.5)   38.8 (31.5; 47.9)   23.5 (16.2; 34.0)
        CRT concurrent                              54    17.9 (14.6; 22.2)   66.7 (55.2; 80.5)   32.0 (21.6; 47.6)   22.5 (12.7; 39.9)
                                                                              **HR (95% CI)**     **p-value**         
  **IIIA *vs*. IIIB**                                                         0.70 (0.58; 0.85)   \< 0.001            
  **IIIA Good *vs*. IIIA Poor**                                               0.54 (0.40; 0.73)   \< 0.001            
  **IIIB Good *vs*. IIIB Poor**                                               0.57 (0.43; 0.76)   \< 0.001            
  **IIIA *vs*. IIIB Good**                                                    0.86 (0.68; 1.09)   0.212               
  **Tri-modality *vs*. Surgery plus adjuvant CT**                             0.47 (0.25; 0.89)   0.021               
  **CRT sequential *vs*. concurrent**                                         0.83 (0.57; 1.20)   0.326               

Good = performance status 0--1 and no weight loss; Poor = performance status 2--3 and/or weight loss ≥ 10%; CRT = chemoradiotherapy; CT = chemotherapy; RT = radiotherapy

\* = Total is not sum of Good and Poor, as some patients had no data about weight loss;

**\*\* =** Stage IIIC in *Union for International Cancer Control* \[UICC\] 8

###### 

Progression free survival according to stage and risk groups

                                     Progression-free survival                                           
  ---------------------------- ----- --------------------------- ------------------- ------------------- -------------------
  **IIIA**                                                                                               
     Total\*                   321   12.5 (11.3; 13.6)           52.9 (47.7; 58.7)   24.1 (19.8; 29.3)   16.8 (13.0; 21.7)
     Good                      223   12.9 (12; 15.2)             55.8 (49.6; 62.7)   27.6 (22.3; 34.3)   19.6 (14.8; 26.0)
     Poor                      75    11.4 (7.9; 13.2)            45.3 (35.4; 58.1)   14.2 (8.1; 25.0)    8.3 (3.8; 18.1)
  **IIIB**                                                                                               
     Total\*                   262   9.9 (9.2; 10.8)             38.5 (33.1; 44.9)   12.8 (9.3; 17.7)    4.3 (1.8; 9.9)
     Good                      146   10.7 (9.6; 12.6)            43.8 (36.5; 52.6)   13.6 (9.0; 20.8)    8.6 (4.7; 15.5)
     Poor                      97    8.6 (7.8; 9.9)              26.8 (19.3; 37.2)   9.9 (5.4; 18.2)     0
     T3N3 and T4N3\*\*         84    9.4 (7.9; 11.3)             34.5 (25.7; 46.3)   10.7 (5.8; 20.0)    2.5 (0.4; 15.1)
  **IIIA+IIIB**                                                                                          
     Total\*                   583   11.2 (10.2; 12.2)           46.5 (42.6; 50.7)   19.0 (16.0; 22.6)   11.5 (8.9; 14.9)
     Good                      369   12.2 (11.0; 13.3)           51.0 (46.2; 56.4)   22.1 (18.2; 26.9)   15.4 (11.9; 19.9)
     Poor                      172   9.2 (8.3; 10.5)             34.9 (28.4; 42.8)   11.7 (7.7; 17.7)    3.7 (1.3; 10.8)
                                     **HR (95% CI)**             **p-value**                             
  **IIIA vs IIIB**                   0.71 (0.59; 0.85)           \< 0.001                                
  **IIIA Good vs IIIA Poor**         0.69 (0.52; 0.92)           0.011                                   
  **IIIB Good vs IIIB Poor**         0.69 (0.53; 0.90)           0.006                                   
  **IIIA vs IIIB Good**              0.80 (0.65; 0.99)           0.037                                   

Good = performance status 0--1 and no weight loss; Poor = performance status 2--3 and/or weight loss ≥ 10%;

\* = Total is not sum of Good and Poor, as some patients had no data about weight loss;

**\*\* =** Stage IIIC in *Union for International Cancer Control* \[UICC\] 8

OS and PFS were longer among patients with PS 0--1 and no weight loss (good prognostic group) than among those with PS 2--3 and/or weight loss ≥ 10% (poor prognostic group) ([Table 5](#j_raon-2020-0026_tab_005){ref-type="table"}; [Table 6](#j_raon-2020-0026_tab_006){ref-type="table"}; [Figure 3](#j_raon-2020-0026_fig_003){ref-type="fig"}). These differences were observed in the

![Overall survival and progression-free survival by performance status and weight loss in all patients, stage IIIA and stage IIIB.](raon-54-209-g003){#j_raon-2020-0026_fig_003}

total study population, in IIIA patients and in IIIB patients. Among the good prognostic group of IIIB patients, the survival outcome was similar to the survival outcome of IIIA patients.

Additional outcome data are summarized in [Tables 5](#j_raon-2020-0026_tab_005){ref-type="table"}, [6](#j_raon-2020-0026_tab_006){ref-type="table"} and [7](#j_raon-2020-0026_tab_007){ref-type="table"} and [Figures 3](#j_raon-2020-0026_fig_003){ref-type="fig"} and [4](#j_raon-2020-0026_fig_004){ref-type="fig"}. Univariate analysis demonstrated longer OS for females, never-smokers, good PS, stage IIIA, mediastinal node verification, and for those with PET/CT or PET staging exam. In contrast, OS was not different between patients with adenocarcinomas and those with squamous cell carcinomas. Including these variables into the multivariate survival proportional hazard model, the differences in OS remained significant for females *versus* males, no weight loss *versus* weight loss, PS 0--1 *versus* 2--3, stage IIIA *versus* IIIB, and pathological verification of mediastinal nodes *versus* no verification. EGFR mutation status was not significant in the multivariate analysis but trend for better survival was found in the univariate model ([Table 7](#j_raon-2020-0026_tab_007){ref-type="table"}). OS was also assessed in various treatment subgroups. Significant survival benefits were seen in patients undergoing surgery compared to patients without surgery (HR = 0.43; 95% CI 0.33--0.56; p-value \< 0.001) and in patients receiving combined treatment modalities compared to patients with a single treatment modality ([Table 5](#j_raon-2020-0026_tab_005){ref-type="table"}, hazard ratios not shown). The best OS outcome was shown for patients receiving trimodality therapy ([Table 5](#j_raon-2020-0026_tab_005){ref-type="table"}). A significant OS difference between concurrent and sequential chemoradiotherapy could not be demonstrated. Time from diagnosis to initiation of treatment start had no impact on outcome (analysis by quartiles, p = 0.585).

![Overall survival by variables.](raon-54-209-g004){#j_raon-2020-0026_fig_004}

###### 

Overall survival according to diagnostic variables

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                  Survival                                            
  ----------------- ---------------- ------ -------------------- -------------------------------- ---------------------- ---------------------------- -------
  **Stage**         IIIA             321    20.0 (17.1; 21.4)                                     **IIIA *vs*. IIIB**:                                

                    IIIB             262    14.4 (13.0; 15.9)    0.70 (0.58; 0.85)                \< 0.001               0.77 (0.62;0.95)             0.017

  **Gender**        Female\          188\   20.4 (16.8; 23.8)\   0.76 (0.62; 0.94)                **Female** *vs*\       0.78 (0.64;0.96)             0.044
                    Male             395    15.4 (14.3; 17.6)                                     . **male**:\                                        
                                                                                                  0.010                                               

  **Smoking**       Current smoker   308    15.3 (14.2; 17.7)                                     **Never-smokers**      **vs**:                      

  **status**        Former smoker    219    18.9 (15.9; 20.6)    Current: 0.54 (0.34; 0.84)       0.007                  Current: 0.71 (0.42;0.22)    0.218

                    Never smoker     42     27.1 (17.0; NA)      Former: 0.61 (0.39; 0.97)        0.036                  Former: 0.75 (0.44;1.30)     0.308

  **Weight loss**   No               406    20.0 (17.9; 21.1)                                     **No *vs*. yes**:                                   

  **≥ 10%**         Yes              120    12.7 (10.8; 14.8)    0.54 (0.43; 0.68)                \< 0.001               0.68 (0.53;0.88)             0.003

                                     146    22.4 (17.7; 26.1)    0 *vs*. ≥ 2: 0.37 (0.28; 0.50)   \< 0.001               0.62 (0.43;0.88)             0.007

  **PS**                             338    15.4 (13.9; 17.2)    1 *vs*. ≥ 2: 0.52 (0.41; 0.66)   \< 0.001               0.69 (0.52;0.91)             0.009

                    ≥2               99     11.6 (8.8; 14.7)     0 *vs*. 1: 0.72 (0.57; 0.92)     0.007                  0.90 (0.68;1.17)             0.422

                    Squamous         309    16.3 (15.0; 19.0)                                     **Adeno *vs***.:                                    

  **Histology**     Adenoca          220    18.1 (14.7; 20.6)    Squam: 0.96 (0.79; 1.18)         0.726                  Squam: 0.93(0.68;1.26)       0.630

                    NOS/others       54     15 (10.1; 20.1)      NOS/oth: 0.79 (0.57; 1.11)       0.18                   NOS/oth:0.96(0.63;1.48)      0.857

  **EGFR**          Positive         14     27.1 (20.3; NA)                                       **Positive *vs***:                                  

  **mutation**      Negative         128    15.8 (13.9; 19.7)    Negative: 0.51 (0.24; 1.10)      0.087                  Negative:0.57(0.25;1.28)     0.176

  **positivity**    Not tested       441    16.5 (15.0; 18.9)    Not tested: 0.52 (0.25; 1.10)    0.087                  Not tested:0.83(0.36;1.89)   0.651

  **Nodes**         No               411    14.4 (13.3;15.9)                                      **Yes *vs*. no**:                                   

  **confirmed**     Yes              172    24.7 (21.0; 28.8)    0.56 (0.45; 0.70)                \< 0.001               0.67 (0.52;0.87)             0.002

  **PET-CT or**     Yes              163    19.6 (17.8; 22.8)                                     **Yes *vs*. no**:                                   

  **PET scan**      No               420    15.4 (14.1; 17.6)    0.73 (0.58--0.91)                0.005                  0.84 (0.66;1.07)             0.160
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

NOS = not otherwise specified; oth = others; nodes confirmed = mediastinal lymph-nodes histologically confirmed; PS = performance status

Discussion {#j_raon-2020-0026_s_004}
==========

Our observational study demonstrated a large heterogeneity in both diagnostic procedures and treatment modalities among patients with locally advanced NSCLC in the real-world setting in Central European countries. The results were based on 583 patients from 16 cancer centres of seven countries. The patient characteristics of our study were slightly different from those of recent phase 3 trials[@j_raon-2020-0026_ref_014], [@j_raon-2020-0026_ref_016], and these differences might be explained, at least partly, by higher smoking rates in Central European countries compared to other countries and the real-world nature of our study. In our study, two thirds were male, about half of the patients were older than 65 years and 7% were never-smokers. These rates are lower in terms of females and never-smokers than in the PROCLAIM trial[@j_raon-2020-0026_ref_016], but similar to those of the PACIFIC trial.[@j_raon-2020-0026_ref_014] The majority of our patients (53%) had squamous cell carcinomas and this frequency is slightly higher than the one (47%) of the PACIFIC trial.[@j_raon-2020-0026_ref_014] The low rate (6%) of NSCLC not otherwise specified confirms that accurate pathological examination is well established in Central European countries. Most patients (83%) had good (WHO 0--1) PS and 70% had no weight loss prior to diagnosis. Tumour stages IIIA and IIIB were diagnosed in 55% and 45% of patients, respectively, and these percentages are similar to those of the PACIFIC trial.[@j_raon-2020-0026_ref_014] Although not mandatory for patients with stage III NSCLC, molecular analyses were performed in selected patients. The EGFR mutation rate of 10% is consistent with the previously reported rate of 13.8% among patients with advanced NSCLC.[@j_raon-2020-0026_ref_017] The percentage of patients with ALK translocations (2%) was in the lower range of stage IV patients[@j_raon-2020-0026_ref_018], [@j_raon-2020-0026_ref_019], but similar to another study.[@j_raon-2020-0026_ref_020] PD-L1 testing was not yet standard for patients with NSCLC stage at the time of our study.

Our real-world data can also be compared with those from other recent real-world studies.[@j_raon-2020-0026_ref_020], [@j_raon-2020-0026_ref_021], [@j_raon-2020-0026_ref_022], [@j_raon-2020-0026_ref_023] All studies were similar in terms of median age (around 65 years), good PS (75--86%), never-smokers (4--9%) and percentage of adenocarcinomas (around 40%). In comparison to our study, the proportion of females were slightly higher in the American study (44.8%) and the Canadian study (46%).[@j_raon-2020-0026_ref_020], [@j_raon-2020-0026_ref_022] The percentages of stage IIIA patients were similar between our and the American study but higher (77%) in the Canadian study.[@j_raon-2020-0026_ref_020], [@j_raon-2020-0026_ref_022]

A major goal of our study was to determine the diagnostic and staging procedures ([Table 2](#j_raon-2020-0026_tab_002){ref-type="table"}). Computer tomography of the chest, supplemented by CT or ultrasonography of the upper abdomen, was performed in most patients. PET-CT (or PET) and brain imaging were performed in only 28% and 20% of patients, respectively. These percentages, however, greatly varied between centres and reached almost 100% in some centres ([Table 2](#j_raon-2020-0026_tab_002){ref-type="table"}). In the Canadian real-world study, 58% of patients received a PET scan as part of staging and 74% had baseline brain imaging.[@j_raon-2020-0026_ref_022] Bronchoscopy was performed in 89% of patients, thereby being the most frequent intervention for obtaining tumour material for histopathological diagnosis. Only 13.5% of patients had histopathological mediastinal nodal staging prior to therapy. The American and Canadian real-world studies did not provide data on histopathological assessment of mediastinal lymph nodes prior to treatment.[@j_raon-2020-0026_ref_020], [@j_raon-2020-0026_ref_022] In a retrospective analysis of 106 patients who had been treated with definitive radiotherapy (plus chemotherapy in most patients), 48.1% of patients had pathological confirmation of nodal disease.[@j_raon-2020-0026_ref_024]

Treatment of our patients involved surgery, radiotherapy and chemotherapy ([Table 4](#j_raon-2020-0026_tab_004){ref-type="table"}). Surgery with and without any other treatment was performed in 23% of all patients, 37.1% and 6.1% of patients with stage IIIA and IIIB, respectively. This percentage is similar to the Canadian study in which 21% of patients underwent surgery, either alone or as part of combined modality therapy. This similarity is somewhat surprising based on the fact that the percentage of our stage IIIB patients was higher than the Canadian one (45% *versus* 33%). Lobectomy and pneumonectomy were performed in 57% and 24% of patients, respectively. The rates of pneumonectomies were similar between our and the Canadian study (23% *versus* 18%). Like in the Canadian study[@j_raon-2020-0026_ref_022], most of our surgical patients (87%) received chemotherapy, more frequently as adjuvant than induction chemotherapy.

Chemoradiotherapy was delivered to 34.3% of our patients ([Table 4](#j_raon-2020-0026_tab_004){ref-type="table"}). The concurrent approach was chosen only in 27% of these patients. This low frequency compared to other studies[@j_raon-2020-0026_ref_021], [@j_raon-2020-0026_ref_022] may be explained by patients unfit for the concurrent approach, limitations in the infrastructure of several centres including long waiting lists, and a stricter definition of concurrent *versus* sequential chemoradiotherapy than in other studies.

Overall, 80.3% of patients received systemic chemotherapy, either alone or combined with other treatment modalities. Radiotherapy alone and BSC alone were given to 11.8% and 5% of patients, respectively ([Table 4](#j_raon-2020-0026_tab_004){ref-type="table"}). These percentages are in agreement with the percentage of patients with poor (WHO ≥2) performance status. Although the proportion of patients with BSC was small and most likely caused by patient selection, it was similar to another study in which radiotherapy and BSC alone were delivered to 11% and 21% of patients, respectively.[@j_raon-2020-0026_ref_024]

Our study confirmed tumour stage (IIIA versus IIIB), PS, prior weight loss and gender as prognostic factors. OS of patients with adenocarcinomas did not differ from the one of patients with squamous cell NSCLC. Patients undergoing surgery had better survival than those without surgery ([Table 5](#j_raon-2020-0026_tab_005){ref-type="table"}). The combination of surgery with chemotherapy and/or radiotherapy was also associated with improved survival outcome. The lack of a survival benefit for our patients undergoing concurrent chemoradiotherapy compared to those undergoing sequential chemoradiotherapy in our real-world study ([Table 5](#j_raon-2020-0026_tab_005){ref-type="table"}) might be explained by the multicentre nature of our study, low number of patients, and the heterogeneity of stage III NSCLC. The survival outcomes were similar between our study and the American real-world study.[@j_raon-2020-0026_ref_020] Median OS times were 20.0 and 22.3 months for stage IIIA patients, respectively, and 14.4 and 14.7 months for stage IIIB patients, respectively. The longer median OS of 27.3 months in the Canadian study can, at least partly, be explained by the higher percentage of stage IIIA patients. The best OS in our study with 64% of patients being alive at three years was seen among patients undergoing trimodality therapy and was consistent with the Canadian study.[@j_raon-2020-0026_ref_022] It remains unclear, however, whether this survival benefit is due to treatment or just selection of patients with good prognostic features. In a randomized trial, the addition of surgery to chemoradiotherapy failed to improve overall survival.[@j_raon-2020-0026_ref_025]

Our observational study has several limitations. Firstly, the findings were based on major academic cancer centres and, therefore, might not be representative for smaller centres. Secondly, there was no even distribution of patients between centres and an abundance of Czech patients was seen. Finally, other patient selection biases including patients lost to follow-up might have also played some role.

Our real-world findings also define areas for future improvements in the management of patients with locally advanced NSCLC in Central Europe. Firstly, the rates of staging by means of PET-CT must be increased, mainly through improving access to these procedures. Secondly, brain imaging should be implemented prior to treatment in all patients who are planned for aggressive treatments such as surgery or chemoradiotherapy. Thirdly, invasive staging of mediastinal lymph nodes prior to treatment should be performed more frequently. In order to achieve these goals, awareness among doctors has to be raised, opportunities for education as well as training of doctors must be increased, and the infrastructure of some centres has yet to be improved.

Conclusions {#j_raon-2020-0026_s_005}
===========

The present real-world study confirmed known prognostic factors and the broad heterogeneity in diagnostic and therapeutic strategies among patients with stage III NSCLC in Central European countries. Rates of PET-CT staging, invasive staging of mediastinal nodes, and brain imaging prior to combined treatments should be increased in the future.
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